New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Ro Khanna (D-Calif.) posted a video on TikTok informing his 400,000 followers of “breaking news” that “the Trump ...

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...

Medicare Part D spending for 10 selected diabetes drugs in the USA totaled $35.8 billion in 2023, an increase of 364% from ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly fivefold to $35.8 ...

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...